id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2019-E-5390-0008,FDA,FDA-2019-E-5390,NOTICE OF FINAL DETERMINATION,Other,Letter(s),2024-08-07T04:00:00Z,2024,8,2024-08-07T04:00:00Z,,2024-08-09T13:31:02Z,,0,0,090000648661ee0f
FDA-2019-E-5390-0007,FDA,FDA-2019-E-5390,Letter to U.S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2022-08-01T04:00:00Z,2022,8,2022-08-01T04:00:00Z,,2022-08-01T13:31:10Z,,0,0,0900006485200274
FDA-2019-E-5390-0006,FDA,FDA-2019-E-5390,Patent Term Extension Approval letter from CDER,Other,Approval,2021-11-05T04:00:00Z,2021,11,2021-11-05T04:00:00Z,,2021-11-05T15:03:45Z,,0,0,0900006484e25910
FDA-2019-E-5390-0005,FDA,FDA-2019-E-5390,"Determination of Regulatory Review Period for Purposes of Patent
Extension; DENGVAXIA",Notice,Determinations,2021-11-04T04:00:00Z,2021,11,2021-11-04T04:00:00Z,2022-01-04T04:59:59Z,2021-11-09T18:03:44Z,2021-24067,0,0,0900006484e18016
FDA-2019-E-5390-0004,FDA,FDA-2019-E-5390,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2021-07-26T04:00:00Z,2021,7,2021-07-26T04:00:00Z,,2021-07-26T17:01:14Z,,0,0,0900006484c0f068
FDA-2019-E-5390-0003,FDA,FDA-2019-E-5390,Letter to U.S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2020-01-07T05:00:00Z,2020,1,2020-01-07T05:00:00Z,,2020-01-07T16:44:41Z,,0,0,0900006484277cd0
FDA-2019-E-5390-0002,FDA,FDA-2019-E-5390,Patent Term Extension Application from Sanofi Pasteur,Other,Application,2019-11-14T05:00:00Z,2019,11,2019-11-14T05:00:00Z,,2019-11-14T15:54:41Z,,0,0,0900006484154f0d
FDA-2019-E-5390-0001,FDA,FDA-2019-E-5390,Letter from U S Patent and Trademark Office,Other,Letter(s),2019-11-14T05:00:00Z,2019,11,2019-11-14T05:00:00Z,,2019-11-14T15:53:12Z,,0,0,0900006484154e68